All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study

The TILTS study is a clinical trial testing an experimental treatment for adults with advanced solid tumours. It is designed for people whose cancers have specific genetic changes called SWI/SNF alterations. The trial uses Tumor Infiltrating Lymphocytes, or TILs. These are natural immune cells collected from a patient's own tumour. Scientists multiply these cells in a laboratory into billions of cancer-fighting cells. Before receiving the cells back through a drip, patients have brief chemotherapy to prepare their body. Afterwards, they receive an immune-boosting medicine called aldesleukin to help the cells work. The main goal is to find out how well this treatment can shrink tumours. Researchers will also monitor safety, side effects, and how long any benefits last. This helps doctors learn if TIL therapy could become a helpful option for hard-to-treat cancers.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBELL
Enrolment target
11
Start
04 Sep 2023

What is this study about?

When cancer spreads or stops responding to regular treatment, doctors look for new ways to help the immune system fight back. This study focuses on advanced solid tumours that have changes in a set of genes known as the SWI/SNF complex. These genetic alterations can affect how tumours grow and how they respond to standard medicines.

The treatment being tested is called TIL therapy. Our immune systems naturally send specialised white blood cells, called lymphocytes, into tumours to attack cancer. However, there are usually not enough of them to win the fight. In this trial, surgeons take a small sample of the tumour so scientists can extract these immune cells. In a special laboratory, they multiply them into vast numbers over several weeks so they can be given back to the patient.

To give the new immune cells the best chance of working, patients first receive a short course of chemotherapy (fludarabine and cyclophosphamide). This clears space in the body's immune system. Patients then receive their grown immune cells through an intravenous drip, followed by doses of a medicine called aldesleukin (Proleukin) to keep the cells active and strong.

This study matters because it explores whether personalised cell therapy can offer a new lifeline for people with specific, hard-to-treat cancers. By testing this approach, researchers hope to see meaningful tumour shrinkage and improve long-term outcomes for patients with few other options.

Key takeaways

  • The study tests a personalised immune cell therapy (TILs) for advanced solid cancers.
  • It is specifically for tumours carrying genetic changes in the SWI/SNF complex.
  • Your own cancer-fighting cells are collected, grown in large numbers in a lab, and returned to you.
  • The treatment requires a hospital stay of a few weeks and involves brief chemotherapy.
  • The main goal is to see if this treatment can safely shrink tumours.

Who may be eligible?

This trial is open to adults aged 18 and over who have an advanced solid cancer. An advanced cancer usually means it has spread to other parts of the body or cannot be safely removed with surgery.

To be considered, your tumour must have specific genetic changes in the SWI/SNF complex. Your medical team can check this using laboratory tests on previously taken tumour samples or a new biopsy. You also need to have a tumour that is safe for doctors to take a small tissue sample from, as this is necessary to collect your immune cells.

Because this treatment is physically demanding, you must be well enough to carry out daily tasks and have reasonably healthy heart, lung, kidney, and liver function. People with certain active infections, significant heart problems, or autoimmune conditions may not be able to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with an advanced solid cancer.
  3. My cancer has a known change in the SWI/SNF genes, or my doctor can test for it.
  4. I have a tumour that can be safely biopsied to collect immune cells.
  5. I am well enough to cope with intensive treatment and a hospital stay.
Answer every question to see your result.

What does participation involve?

Taking part in this study involves several distinct steps over a few months, followed by regular check-ups. First, you will have tests including blood samples, scans, and heart checks to confirm the trial is safe for you. If eligible, you will have a small procedure or surgery to remove a piece of tumour tissue so your immune cells can be grown in a laboratory.

Once your cells are ready, you will be admitted to hospital. You will receive chemotherapy over a few days to prepare your body, followed by the infusion of your grown immune cells. After the cell infusion, you will receive doses of aldesleukin through a drip. Because these medicines can cause temporary side effects, you will stay in hospital under close observation until you recover, which often takes two to three weeks.

After leaving hospital, you will have regular follow-up visits. These involve physical checks, blood tests, and scans (such as CT or MRI scans) to see how your tumour is responding. Follow-up visits usually happen every few weeks at first, then become less frequent over several months to years.

Potential risks and benefits

The potential benefit of taking part is that the treatment may shrink your tumour or slow its growth, especially if other treatments have stopped working. However, there is no guarantee that the treatment will help everyone. The risks include significant side effects from the chemotherapy and the immune-boosting medicine, such as fatigue, an increased risk of infections, fever, low blood pressure, nausea, and fluid build-up. These treatments require close hospital care to manage symptoms safely. Taking part is completely voluntary, and you are free to leave the trial at any point without it affecting your standard NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Spain

Common questions

What does TIL stand for?

TIL stands for Tumor Infiltrating Lymphocytes. These are your own immune cells that have naturally entered your tumour to fight cancer.

Will I have to stay in hospital?

Yes. You will need to stay in hospital for the chemotherapy, cell infusion, and recovery period, which usually lasts two to three weeks.

How do doctors know if I have the SWI/SNF alteration?

The hospital laboratory can test a piece of your tumour tissue from a previous surgery or biopsy to check its genetic makeup.

Is this chemotherapy or immunotherapy?

It is primarily an advanced cell-based immunotherapy, but it uses a short course of chemotherapy beforehand to prepare your body for the cells.

Can I leave the study if I change my mind?

Yes. Joining a clinical trial is entirely your choice, and you can withdraw at any time without giving a reason.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A phase 2, Multicenter Study of TILs Treatment in Advanced T…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.